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R. Scott Thurston, MD, FACS
EDITORIALThurston EditorialThe experience of having acquired hepatitis C virus (HVC)
in the operating room as a practicing cardiovascular surgeon
has led me to review the literature and to try and define the
proper treatment and subsequently the social implications
and options related to resuming practice as quickly as possi-
ble. Below is what I have gleaned from the literature and my
own experience in the hope of providing recommendations
for the surgical community.
Hepatitis C virus is a worldwide problem with an esti-
mated 170 million people infected, including 1.4% of the
US population. It can lead to cirrhosis and liver cancer in
the minority (20%) of patients.1 The prevalence is as high
as 22% in Egypt and averages 3% in China. The incidence
in the United States has been declining steadily, and approx-
imately 20,000 cases are now thought to occur per year.2 No
vaccine is available. Seroconversion or illness with acute
HCV in a practicing surgeon has legal, ethical, and personal
considerations, as transmission from surgeon to a patient is
well documented.
Hepatitis C virus was discovered and named in 1989. Be-
fore this it was known as ‘‘non A non B hepatitis.’’ It is un-
related to hepatitis A or B virus. It is a single-stranded RNA
virus that at 50 nm is smaller than the wavelength of light.
It is 9400 base pairs long, and the coding regions for the
3 structural and 7 nonstructural viral proteins are known.
The virus occurs in 6 major genotypes with more than 80
subtypes. The genotypes occur in specific geographic re-
gions of the human population. The only host is the human
hepatocyte, where viral replication rates can approach
a trillion per day.3
Hepatitis C virus is transmitted by blood-borne routes, in-
cluding transfusion, injection drug use, contaminated medi-
cal equipment, and tattoos, and less commonly by sexual
contact, perinatally, or health care worker needle stick. In de-
veloped countries where blood is screened, the major trans-
mission is seen in drug users and patients on dialysis. In the
developing world, blood transfusion, the reuse of needles,
and the unnecessary administration of medications by injec-
tion are contributory. For example, in Egypt the diseases of
visceral leishmaniasis and schistosomiasis are treated by in-
jection often with reused needles. Transmission in monoga-
mous sexual couples is rare or nonexistent.4
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85% of patients acquire the virus without knowledge that
they have become infected. If symptoms occur, they are
jaundice, indigestion, fatigue, myalgia, and right upper
quadrant pain. Approximately 25% of patients will clear
the virus spontaneously, but 75% go on to have a persistent
viremia. Clearance of the virus either spontaneously or with
treatment is considered a cure.5 The occurrence of acute
jaundice and symptoms is associated with a vigorous im-
mune response and a higher rate of clearance.6 The immune
response is led by CD4 T cells and subsequently by CD8
killer T cells. A prolonged response by these cells correlates
with clearance. However, no long-term immunity is pro-
duced and reinfection with HCV is possible. Other factors
that may be associated with spontaneous clearance are geno-
type 3, female sex, a younger age, a low viral load, and Cau-
casian race. Chronic HCV infection leads to cirrhosis and
liver cancer in the minority of patients.
Transmission to a health care worker by needle stick is
a real phenomena and of increasing importance in the
United States. The risk per stick from an infected patient
seems to be approximately 1%.7,8 The lifetime risk of sero-
conversion to a cardiac surgeon over a 30-year career is as
high as 5%.9 Transmission to patients by the operating sur-
geon has occurred in gynecology, orthopedics, dentistry,
and cardiac surgery. Mathematic modeling with reasonable
assumptions indicate that transmission would occur in 1 of
10,000 cases.10 This risk is lower than that from screened
blood transfusion.
After exposure, seroconversion occurs at approximately
20 to 30 days, and symptoms, if they are to occur, occur at
an average of 50 days. At 1 to 3 months, elevated alanine
aminotransferase levels up to 20 times that of normal levels
may be seen. Fulminant hepatic failure is rare. If antibodies
against HCV are detected, it is mandatory to confirm the
result with quantitative HCV polymerase chain reaction.
These assays now are accurate to 2 copies of the RNA virus
per milliliter of blood. The detection of HCV RNA without
demonstrable antibodies suggests acute infection because
viremia may precede antibody production. There are no spe-
cific recent guidelines for postexposure by needle stick that
take into account the recent treatment literature. It now
seems reasonable to test liver function studies (alanine ami-
notransferase), HCV antibody, and HCV RNA polymerase
chain reaction at baseline and at 1, 2, 3, and 6 months.
This would allow for the early institution of treatment if
desired by the patient.
The goal of treatment is sustained virologic response. This
is defined by the lack of detectable virus at 6 months after the
end of treatment. This is compatible with cure because
relapse rates are extremely low. For acute HCV, currentardiovascular Surgery c Volume 137, Number 3 519
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Ltreatment has evolved to pegylated interferon alpha-2b at
a dose of 1.5 mg/kg. This is a subcutaneous injection given
weekly for 24 weeks. Interferons are cytokine proteins pro-
duced by leukocytes in response to double-stranded RNA
seen during viral replication. They are responsible for pro-
ducing flu-like symptoms, and therefore the side effects
are fever, myalgias, fatigue, insomnia, and neurologic symp-
toms such as depression. Some studies indicate an early
responder with no detectable virus at 4 weeks need only
be treated for 3 months. The addition of ribavirin as used
for chronic HCV has not been shown to be additive for acute
HCV.11 The current recommendations for when to institute
treatment are a balance between the known chance of spon-
taneous clearance and the recent indications in the literature
that early therapy may increase clearance rates. In any case,
treatment should be started within 3 months of symptoms.12
Patients with genotype 1 may benefit from early treatment.13
A surgeon might choose immediate treatment to maximize
his/her chances of sustained virologic response.
In pursuing medical, legal, malpractice, ethical, and
clinical guidelines, there is little guidance available. It seems
uniformly to make sense that a surgeon with an acute infec-
tion and a high viral load should not participate in operations.
Also, if one achieves a sustained virologic response compat-
ible with a cure, one would not limit one’s practice. In the
case of a surgeon who is persistently viremic after 6 months
(ie, chronic HCV), the recommendations differ. In England,
Ireland, and Australia,14 guidelines are in place that discour-
age or prohibit a surgeon from performing exposure-prone
procedures. In theUnited States, the official recommendation
of the Centers for Disease Control is that chronic HCV not
limit a health care worker’s ability to practice.15 The stance
of the American College of Surgeons is that because of the
extremely low incidence of surgeon-to-patient transmission,
a surgeon not limit his/her practice and has no duty to disclose
his/her status to the patient. The college, however, states
a surgeon should know his/her own HCV status.16 It has
been suggested that because of the high incidence of cardiac
surgeon injury during closure with sternal wires, perhaps an
assistant should close. Other than the above, there is no cur-
rent call to test all surgeons and have their antibody status
known, nor is it recommended to test all patients undergoing
surgery.520 The Journal of Thoracic and Cardiovascular SuInmyowncase, I choosenot to try andkeep any secrets, from
partners, colleagues, or hospital staff.We informed each hospi-
tal administration ofmy status, and I voluntarilywithdrew from
the operating room. Regular meetings with the medical staff
offices were undertaken, and they had access to my medical
records. Consideration must be given to instituting discussions
with malpractice carriers and disability insurers.
Recommendations from a knowledgeable hepatologist
were taken into account to enable me to make rounds and
see office patients. Personally, I chose immediate treatment
with interferon alpha-2b, and I took ribavirin. At the present
time, my most recent viral load is zero and I have resumed
unrestricted practice.
References
1. Hoofnagle JH.Course and outcome of hepatitis C.Hepatology. 2002;36(5 Suppl. 1):
S21-9. Review.
2. Centers for Disease Control and Prevention. Surveillance for Acute Viral Hsepa-
titis United States. 56th ed. Atlanta, GA: Centers for Disease Control and Preven-
tion; 2005.
3. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet. 2008;372:321-32.
4. Vandelli C, Renzo F, Romano L, et al. Lack of evidence of sexual transmission of
hepatitis C among monogamous couples: results of a 10 year prospective study.
Am J Gastroenterol. 2004;99:855-9.
5. Weigand J, Jackel E, Cornberg M, et al. Long term follow up after successful in-
terferon therapy of acute hepatitis C. Hepatology. 2004;40:98-107.
6. Santantino T, Medda E, Ferrari C, et al. Risk factors and outcome among a large
patient cohort with community acquired hepatitis c in Italy. Clin Infect Dis. 2006;
43:1154-9.
7. Kubitschke A, Bader C, Tillman HL, et al. Injuries from needles contaminated
with hepatitis C virus, how high is the risk of seroconversion really? Der Internist
(Berl). 2007;48:1165-72.
8. De Carli G, Puro V, Ippolito G. Studio Italiano Rischio Occupazionale da HIV
Group. Risk of hepatitis C virus transmission following percutaneous exposure
in healthcare workers. Infection. 2003;31:22-7.
9. Kuo Y, Fabiani J, Mohamed A, et al. Decreasing occupational risk related to
blood-borne viruses in cardiovascular surgery in Paris, France. Ann Thorac
Surg. 1999;68:2267-72.
10. Ross RS, Viazov S, Roggendorf M. Risk of hepatitis C transmission from infected
medical staff to patients: model based calculations for surgical settings. Arch In-
tern Med. 2000;160:2313-6.
11. Calleri G, Cariti G, Gaiottino F, et al. A short course of pegylated interferon alpha
in acute HCV hepatitis. J Viral Hepat. 2007;14:116-21.
12. Nomura H, Sou S, Tanimoto H, et al. Short term interferon alpha therapy for acute
hepatitis C: a randomized controlled study. Hepatology. 2004;39:1213-9.
13. Watson K. Sharps injuries and hepatitis C risk. Med J Aust. 2004;181:366-7.
Accessed July 21, 2008.
14. Available at: www.cdc.gov/hepatitis/HCV/HCVfaq.htm.
15. Available at: www.facs.org/fellows_info/statements/st_22_.html. Accessed April
2004.
16. Available at: www.facs.org/fellows_info/statements/st_22_.html. Accessed April
2004.rgery c March 2009
